Evaluation of Aldrithiol-2-Inactivated Preparations of HIV Type 1 Subtypes A, B, and D as Reagents to Monitor T Cell Responses
- 1 April 2007
- journal article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 23 (4) , 532-542
Abstract
The development of HIV vaccines is an urgent priority and there is need to generate reagents representing multiple subtypes that can be used to screen HIV-1-specific responses. We used Aldrithiol-2 (AT-2), a mild oxidizing reagent, to eliminate the infectivity of HIV while maintaining its structure and ability to be processed for presentation to T cells. Inactivated subtype A, B, and D viruses were evaluated for their ability to stimulate T cell responses in PBMC samples from 18 U.S. subjects infected with HIV-1 subtype B and 32 Ugandan subjects infected with subtypes A and D or recombinants AC and AD. Five HIV-1-negative samples were also analyzed. T cell responses to AT-2-inactivated viral isolates were monitored by interferon-gamma (IFN-gamma) intracellular cytokine secretion (ICS) analysis; matched microvesicle preparations served as negative controls. Among the 18 subtype B infected subjects, 39% had CD3(+) CD4 (+) IFN-gamma responses and 67% had CD3(+) CD8(+) IFN-gamma responses. Of the 32 Ugandan subjects, 34% demonstrated CD3(+) CD4(+) IFN-gamma responses and 78% demonstrated CD3(+) CD8(+) IFN-gamma responses. Both subtype-specific and cross-reactive responses were observed. Responses to the AT-2 viruses tended to be lower in magnitude than those detected by a set of overlapping gag peptides. Robust lymphoproliferative responses to AT-2 viruses were seen in a subset of subjects. In conclusion, AT-2-inactivated HIV-1 virions stimulated both CD4 and CD8 HIV-1-specific responses and may provide an additional reagent for screening HIV-1-specific responses in HIV seropositives and vaccinees.Keywords
This publication has 67 references indexed in Scilit:
- Proliferative Capacity of Epitope-Specific CD8 T-Cell Responses Is Inversely Related to Viral Load in Chronic Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2007
- Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell EpitopesJournal of Virology, 2006
- Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactionsBlood, 2006
- Tracking the killersAIDS, 2004
- Recognition of cmv pp65 protein antigen by human cd4 t-cell lines induced with an immunodominant peptide poolHuman Immunology, 2004
- Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cellsBlood, 2004
- Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virionsProceedings of the National Academy of Sciences, 2003
- Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of ImmunityThe Journal of Infectious Diseases, 2003
- Infectious and Whole Inactivated Simian Immunodeficiency Viruses Interact Similarly with Primate Dendritic Cells (DCs): Differential Intracellular Fate of Virions in Mature and Immature DCsJournal of Virology, 2002
- Parameters Influencing Measurement of the Gag Antigen-Specific T-Proliferative Response to HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2000